Limits...
Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY - J Immunol Res (2014)

Bottom Line: Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls.In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive.This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

View Article: PubMed Central - PubMed

Affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.

ABSTRACT
Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

Show MeSH

Related in: MedlinePlus

Sensitivity and specificity of ELISA based on combined seven TAAs (cyclin B1, survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1) for differentiating between PCa (n = 174) and normal controls (n = 89).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016862&req=5

fig4: Sensitivity and specificity of ELISA based on combined seven TAAs (cyclin B1, survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1) for differentiating between PCa (n = 174) and normal controls (n = 89).

Mentions: It has been demonstrated that although no single TAA was uniquely associated with a particular type of cancer when panels or mini-arrays of TAAs were used in antigen platforms, some types of cancer were more reactive to certain specific TAAs. In this study, cyclin B1 appeared to be the most reactive antigen in prostate cancer and an analysis was performed to determine whether a subset and not necessarily all the 15 TAAs (Table 1) was sufficient to achieve optimal antibody frequency. Besides cyclin B1, there were six other autoantibodies that showed significant higher frequency in PCa sera than in NHS, such as survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1. Subsequently, we used ROC curve to analyze the diagnostic value of combination of these 7 autoantibodies in PCa compared to normal individuals, which showed that the sensitivity reached 80.5% and the specificity 91% with AUC at 0.942 (95% CI: 0.916–0.968) (Figure 4).


Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY - J Immunol Res (2014)

Sensitivity and specificity of ELISA based on combined seven TAAs (cyclin B1, survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1) for differentiating between PCa (n = 174) and normal controls (n = 89).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016862&req=5

fig4: Sensitivity and specificity of ELISA based on combined seven TAAs (cyclin B1, survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1) for differentiating between PCa (n = 174) and normal controls (n = 89).
Mentions: It has been demonstrated that although no single TAA was uniquely associated with a particular type of cancer when panels or mini-arrays of TAAs were used in antigen platforms, some types of cancer were more reactive to certain specific TAAs. In this study, cyclin B1 appeared to be the most reactive antigen in prostate cancer and an analysis was performed to determine whether a subset and not necessarily all the 15 TAAs (Table 1) was sufficient to achieve optimal antibody frequency. Besides cyclin B1, there were six other autoantibodies that showed significant higher frequency in PCa sera than in NHS, such as survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1. Subsequently, we used ROC curve to analyze the diagnostic value of combination of these 7 autoantibodies in PCa compared to normal individuals, which showed that the sensitivity reached 80.5% and the specificity 91% with AUC at 0.942 (95% CI: 0.916–0.968) (Figure 4).

Bottom Line: Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls.In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive.This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

View Article: PubMed Central - PubMed

Affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.

ABSTRACT
Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

Show MeSH
Related in: MedlinePlus